Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company's lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.
http://www.priceseries.com/trade/ZFGN-Zafgen-Inc-stock-gains-46-percent-a-Trade-Record-by-priceSeries-2017122020180129.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments